Abstract 11P
Background
Acute myeloid leukemia (AML) is a genetically diverse hematological disorder marked by abnormal differentiation and clonal proliferation of myeloid progenitor cells in the bone marrow, with various genetic and epigenetic alterations. Ferroportin, encoded by the SLC40A1 gene, is the sole protein responsible for cellular iron export. However, the expression, molecular mechanisms, and interactions of SLC40A1 in AML remain unclear. This study aims to elucidate the molecular functions, clinical, and prognostic value of SLC40A1 in AML.
Methods
We examined the expression level of SLC40A1 in AML (n=173) and control (n=70) samples. Correlation analysis was performed to identify genes potentially associated with SLC40A1 expression using the Linked Omics database. The DNA methylation status of SLC40A1 was evaluated using the MEXPRESS database. Gene set enrichment analysis (GSEA) was conducted to explore the molecular mechanisms of SLC40A1 in AML. The relationship between SLC40A1 expression and immune checkpoints was studied using the SANGER Box 3.0 database.
Results
SLC40A1 mRNA was significantly overexpressed in AML cohorts compared to normal samples and was associated with poor overall survival (P < 0.05). Correlation analysis revealed that SLC40A1 was positively correlated with DNAJC6, CD59, and CAPRIN2, and negatively correlated with MSLN, MYH11, and PLCD3 (PCC < 0.80). Lower methylation levels of SLC40A1 were observed in AML, which were negatively associated with its expression. Gene enrichment analysis showed SLC40A1 was involved in biological processes such as lymphocyte homeostasis, cell communication, and differentiation. In terms of molecular functions, SLC40A1 was enriched in iron ion transmembrane transporter activity, growth factor binding, and catalytic activity. KEGG pathway analysis indicated enrichment in hematopoietic stem cell differentiation, TGF-beta signaling, and pathways regulating pluripotency of stem cells. Additionally, SLC40A1 expression was positively correlated with immune checkpoints including CD40, CD44, and CD80.
Conclusions
SLC40A1 may serve as a potential prognostic biomarker and therapeutic target for effective AML management.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract